Latest news with #AkebiaTherapeutics
Yahoo
5 days ago
- Business
- Yahoo
Akebia Therapeutics to Present at Canaccord Genuity's 45th Annual Growth Conference
CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, will participate in a Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference on Wednesday, August 13 at 1:30 PM EDT. The conference will take place August 12-14, 2025 in Boston. A webcast of the presentation can be accessed through the 'Investors' section of Akebia's website at following the conference. About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at which does not form a part of this release. Akebia Therapeutics ContactMercedes Carrascomcarrasco@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
01-08-2025
- Business
- Globe and Mail
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 238,500 shares of Akebia's common stock on July 31, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $3.69 per share, which is equal to the closing price of Akebia's common stock on the grant date. The stock options vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee's continued service with Akebia. Each stock option has a 10-year term and is subject to the terms and conditions of Akebia's inducement award program and a stock option agreement covering the grant. About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at which does not form a part of this release.
Yahoo
31-07-2025
- Business
- Yahoo
Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights
Akebia to Host Conference Call on August 7, 2025, at 8:00 a.m. EDT CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, August 7, 2025, at 8:00 a.m. EDT to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time. A live webcast of the conference call will be available via the Investors section of Akebia's website at: An online archive of the webcast can be accessed via the Investors section of Akebia's website at About Akebia TherapeuticsAkebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at which does not form a part of this release. Akebia Therapeutics ContactMercedes Carrascomcarrasco@ 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
25-07-2025
- Business
- Yahoo
H.C. Wainwright Rates Akebia Therapeutics (AKBA) Stock Buy
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 10 Best Performing Penny Stocks So Far in 2025. On June 4, H.C. Wainwright analysts initiated coverage of Akebia Therapeutics, Inc. (NASDAQ:AKBA) and gave it a 'Buy' rating with a price target of $8. This decision was based on confidence in the company's drug, Vafseo (vadadustat), which is used to treat anemia in adults with chronic kidney disease (CKD) who are on dialysis. A biopharmaceutical team in a laboratory analyzing new compounds to develop therapeutics. In March 2024, Akebia Therapeutics, Inc. (NASDAQ:AKBA) received FDA approval for Vafseo (vadadustat) for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months. Vafseo became available in the US market starting January 2025. Currently, Vafseo is being rolled out for dialysis patients. However, there is also potential for expansion in the non-dialysis segment. Akebia Therapeutics, Inc. (NASDAQ:AKBA) plans to start a Phase 3 trial for the use of Vafseo (vadadustat) in treating anemia in late-stage CKD patients who are not on dialysis. H.C. Wainwright analysts expect further growth for Akebia Therapeutics, Inc. (NASDAQ:AKBA) as the drug gains acceptance among dialysis organizations, including large ones. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a fully integrated biopharmaceutical company focused on developing and commercializing therapies for kidney disease. While we acknowledge the potential of AKBA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
22-07-2025
- Business
- Yahoo
Akebia Therapeutics (AKBA) Kidney Therapy Vafseo Gaining Market Share
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the best high-return penny stocks to buy now. On July 14, 2025, Akebia shared key updates during the H.C. Wainwright Kidney Conference, emphasizing the rollout of its oral anemia treatment Vafseo, prescribed by over 640 physicians in Q1. A close up of a researcher in a laboratory, examining a new biopharmaceutical drug used to treat resistant bacterial infections. With initial pricing at $15,500 annually and post-TDAPA rates expected near $2,500, Akebia targets a $4–5 billion opportunity by expanding to non-dialysis CKD patients. A pilot launch with a major dialysis provider is set for Q3, covering 75–200 clinics, with broader availability expected in Q4 and a Phase 3 trial planned for later this year. Akebia also reaffirmed strong sales momentum for Auryxia, its existing kidney treatment, despite generic competition. The company's R&D pipeline includes AKB-909O for acute kidney injury and AKB-10108 for retinopathy of prematurity. Akebia aims to position Vafseo as the standard of care across CKD stages, supported by its ongoing VOICE trial targeting reduced hospitalizations. This strategic push underscores Akebia's focus on delivering innovative solutions for chronic kidney care and expanding market reach amid competitive challenges. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company focused on developing and commercializing therapies for kidney disease. It has two FDA-approved products, Auryxia (ferric citrate) and Vafseo, both of which target complications of kidney disease, such as anemia and hyperphosphatemia. While we acknowledge the potential of AKBA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Chemical Stocks to Buy According to Billionaires and 7 Most Undervalued Pot Stocks To Buy According To Analysts. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
